- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Ascendis Pharma AS(ASND)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Advisory Performance History (Simulated)
Upturn Advisory & Investor View for ASND
11/13/2026: ASND (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Ascendis Pharma AS is a commercial-stage biopharmaceutical company leveraging its proprietary TransCon platform to develop specialized treatments for rare endocrine diseases. The company's primary strength lies in the successful commercialization of Skytrofa and a robust pipeline addressing high unmet medical needs. Key growth opportunities stem from label expansions and new product rollouts across global markets, though execution risks and ongoing operating expenses remain key considerations. The stock is best suited for growth-oriented investors willing to monitor regulatory milestones, reimbursement trends, and commercial scaling progress.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | Ascendis delivers high revenue growth rates driven by the commercial scaling of its rare disease portfolio. |
| Momentum investor | Strong fit while signal remains positive | Stock price reactions to regulatory decisions and commercial milestones frequently create strong upward momentum trends. |
| Value investor | Weak fit | The company trades on pipeline potential and revenue growth rather than near-term earnings or book value. |
| Dividend investor | Weak fit | Ascendis does not pay dividends, directing all cash flow toward clinical development and commercial expansion. |
| Low-risk investor | Weak fit | High clinical, regulatory, and price volatility typical of clinical-stage and commercial biotech companies creates substantial risk. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Biotech market sentiment and binary clinical trial or regulatory events trigger sharp share price swings. |
| Valuation risk | Medium / high | Valuations are heavily dependent on long-term cash flow assumptions for pipeline products. |
| Competition risk (rare disease and endocrinology) | Medium | Well-capitalized pharmaceutical rivals continually attempt to develop alternative long-acting therapies. |
| Business quality | Medium / high | Proprietary TransCon technology creates a defensible scientific moat, though commercial execution is critical. |
| Dividend income | Low / none | No dividend is paid, offering zero income return for yield-focused investors. |
| Execution risk | High | Commercial uptake, market access, and global reimbursement negotiations dictate top-line success. |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 18.06B USD | Price to earnings Ratio 18.11 | 1Y Target Price 315.2 |
Price to earnings Ratio 18.11 | 1Y Target Price 315.2 | ||
Volume (30-day avg) 726.9K shares | Beta 0.48 | 52 Weeks Range 188.08 - 282.15 | Updated Date 11/15/2026 |
52 Weeks Range 188.08 - 282.15 | Updated Date 11/15/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) 15.21 |
Sector & Industry Intelligence
Sector
Healthcare
Bullish- Sentiment
- Strong Bullish
- Momentum
- Momentum Steady
- BUY participation
- 62.6%
- Active BUY / eligible
- 72 / 115
- 30-Day BUY Count Change
- +35
- Market state
- Strong Bullish
The number of qualifying BUY stocks has remained relatively stable.
Industry
Biotechnology
- BUY participation
- 45.5%
- Active BUY / eligible
- 20 / 44
- 30-Day BUY Count Change
- +13
Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.
Price Behavior

Steady Uptrend
The stock demonstrates consistent and steady upward price momentum.

Moderately Choppy
The stock has experienced noticeable price swings while retaining some directional structure.
Analysis of Past Performance
Type Stock | Historic Profit -44.61% | Avg. Invested days 29 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Advisory Rating ![]() | Upturn Advisory Performance | Stock Returns Performance |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals 
Financial Health Rating 
Growth Momentum Score 
Ownership 
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue) 
Economic Dimensions
Quantitative Style Profile 
Style Classification
Quality Focused
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Skytrofa Product Sales | Global commercial sales of Skytrofa for pediatric growth hormone deficiency. | This is the core revenue engine currently driving the company's financial growth. |
| Endocrinology Pipeline Commercialization | Upcoming and newly approved treatments like Yorvipath for hypoparathyroidism. | Represents the next wave of diversification and revenue expansion beyond growth hormone products. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2026-11-12 | When Before Market | Estimate 1.13 | Actual 1.24 |
Profitability
Profit Margin 72.88% | Operating Margin (TTM) 30.94% |
Management Effectiveness
Return on Assets (TTM) 12.99% | Return on Equity (TTM) 132.2% |
Valuation
Trailing PE 18.11 | Forward PE 23.36 | Enterprise Value 17.49B | Price to Sales(TTM) 15.02 |
Enterprise Value 17.49B | Price to Sales(TTM) 15.02 | ||
Enterprise Value to Revenue 13.16 | Enterprise Value to EBITDA 44.67 | Shares Outstanding 65.60M | Shares Floating 65.56M |
Shares Outstanding 65.60M | Shares Floating 65.56M | ||
Percent Insiders 0.9 | Percent Institutions 101 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.

